News

Tocilizumab Continues to Benefit sJIA Patients Over Time

Publish date: July 11, 2011

 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

The TENDER trial was sponsored by Roche, the company that markets tocilizumab. Dr. De Benedetti said he has been a consultant to Bristol-Myers Squibb, Hoffmann-La Roche, and Pfizer, and he has received research support from Hoffmann-La Roche. Dr. Woo said she had no disclosures.

Pages

Recommended Reading

Tocilizumab Safety Confirmed in Real-World Setting for RA
MDedge Internal Medicine
Topical Combo Shows Early Promise in Moderate Psoriasis
MDedge Internal Medicine
ACPA-Negative RA Incidence Spikes During First Postpartum Year
MDedge Internal Medicine
Rheumatoid Arthritis Patients Have High Expectations for Biologics
MDedge Internal Medicine
Periprosthetic Joint Infections Not Increased by RA Biologics
MDedge Internal Medicine
GI Perforation Rare in Rheumatoid Arthritis Patients
MDedge Internal Medicine
RA and SLE Risk Factors Remain for Mothers and Babies
MDedge Internal Medicine
SLE: Belimumab Safety, Efficacy Sustained Over 6 Years
MDedge Internal Medicine
Fulranumab Shows Efficacy for Osteoarthritis Pain
MDedge Internal Medicine
HPV Vaccine Does Not Induce Lupus Flares
MDedge Internal Medicine